A Home Reading Room for Peptide Science

The short version

Think of this site as a small reading room, not a pharmacy. On the shelf are four research peptides — short chains of amino acids that scientists study for how they might support tissue repair, cellular energy, sexual health, or skin structure. Each one has its own body of published research, and each is at a very different stage: one is an FDA-approved prescription medicine, one is a widely sold dietary supplement, and two are studied mainly in labs and small human pilot trials.

We are not a clinic, a pharmacy, or a supplier. Every page here is written to be read at a desk, checked against its citations, and questioned. Where people in research-use or skincare communities report an effect that has not been proven in a controlled trial, we say so plainly and label it anecdotal, not clinical evidence. Nothing on this site is a dose to take or an instruction to follow — it is a summary of what has been published, with the numbers and the citations that back each claim.

Welcome to the reading room

This is a home reading room for peptide science — the plain-English shelf. The four peptides gathered here — BPC-157, NAD+, PT-141, and GHK-Cu — do not share a single mechanism or a single medical category. What they share is that each one has generated real scientific interest, real controversy, and a real gap between what is published in the literature and what circulates informally online. That gap is exactly what this shelf exists to close.

GHK-Cu sits at the front of the room. It has the deepest and longest human clinical record of the four — decades of topical dermatology and hair-growth research — which makes it a useful anchor for reading the others. BPC-157, by contrast, is almost entirely a rodent story so far, with only a handful of small human pilot reports published as of 2025. NAD+ is a case study in the gap between a supplement that reliably raises a blood marker and a supplement that has been shown to change a hard clinical outcome. PT-141 is the one FDA-approved drug on the shelf, with a defined label, a defined population, and a defined dose — everything outside that label is, by definition, unstudied territory.

Reading across all four side by side is the point of a reading room: it becomes quickly obvious how differently "peptide" research can be conducted, funded, and reported, and how much that variation matters when weighing a claim.

What are research peptides?

Peptides are short chains of amino acids — the same building blocks that make up proteins, just far smaller, usually only a handful to a few dozen residues long. Some, like GHK-Cu, occur naturally in the body (it is released when type I collagen breaks down) and are then synthesized for study or for cosmetic formulation. Others, like PT-141, are synthetic analogues engineered from a natural hormone (alpha-melanocyte-stimulating hormone) to survive longer in the body and act more selectively. NAD+ is technically a dinucleotide coenzyme rather than a peptide, but it is grouped with this research-peptide category because it is studied, marketed, and discussed alongside them in the same wellness and longevity literature.

The research status of a compound is not fixed by its chemistry — it is a matter of regulatory record. PT-141 (bremelanotide) is FDA-approved as a prescription injection for one specific diagnosis in one specific population; anything outside that use is off-label and unapproved. NAD+ and its precursors (NMN, nicotinamide riboside) are sold as dietary supplements, a category with a lower evidentiary bar than a drug approval. BPC-157 and injectable or systemic GHK-Cu are, as of this writing, research chemicals: sold for laboratory research use only, with no approved human indication and no regulatory oversight of purity or dose. Reading peptide research responsibly starts with knowing which of these four categories a given compound actually sits in — this shelf lays that out, compound by compound.

How to read this shelf

Every compound page on this site follows the same structure so that comparison is easy. A plain-English on-ramp opens each page, written for a reader with no scientific background. Below that, What it is covers the molecule's structure and origin; How it works covers the proposed mechanism; What the research shows walks through the published findings that ground every claim on the page, cited by number; and Reported effects, cautions & safety separates what community members say they experience — always labeled anecdotal — from the safety cautions the published literature actually supports. Every numbered claim links to the full citation on the references page, so nothing here asks to be taken on faith. For the four compounds lined up against each other on one page, go straight to the comparison.